Ad
related to: triple therapy for hepatitis c patients
Search results
Results from the WOW.Com Content Network
Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. [2] It is specifically used for hepatitis C genotype 1 and 4. [2] Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. [2] Cure rates are in 80s to 90s percent.
The RESPOND-2 trial [11] studied patients with chronic hepatitis C genotype 1 who did not have a sustained response to therapy with peginterferon-ribavirin therapy. All patients received a month of peginterferon alfa-2b and ribavirin before being randomized to one of three arms. The first arm received placebo plus peginterferon-ribavirin for 44 ...
The cost of telaprevir-based triple therapy for hepatitis C is $189,000 per sustained viral response. [11] On August 12, 2014, Vertex Pharmaceuticals announced that it would discontinue production of its brand of telaprevir, Incivek, due to falling demand for the drug caused by competition from newer hepatitis C treatments. [12]
[6] [3] Hepatitis C causes inflammation of the liver that eventually leads to diminished liver function or even failure. [7] Zepatier is indicated for treatment with or without use of ribavirin, as well. [5] Zepatier has shown enough efficacy to be considered a first line of treatment for first-time patients with GT 1a and 1b, with or without ...
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. [1] After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [2] [3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication ...
It can triple to as much as $628.90 a month ... when treatment is most likely to work best.” ... cervical and vaginal cancer, colorectal cancer, depression, diabetes, Hepatitis B and C, HIV ...
Daclatasvir is used only in combination therapy for the treatment of hepatitis C genotype 1, 3, or 4 infections; the agents used in combination, which include sofosbuvir, ribavirin, and interferon, vary based on the virus genotype, whether the person has cirrhosis and if a liver transplantation took place.
Ad
related to: triple therapy for hepatitis c patients